Literature DB >> 22993655

Successful use of topical "Ankaferd Blood Stopper" for repetitive bleedings in an infant with infantile hemangioma.

Ali Annagür1, Hüseyin Altunhan, Murat Konak, Rahmi Ors.   

Abstract

Infantile hemangioma (IH) is the most common vascular tumor of childhood. A major feature of this tumor is rapid growth during a proliferation phase in the first year of life, followed by contraction through a slow involution phase. Several complications may emerge during this course. Bleeding at the site of the lesion and infection are the most common complications. 'Ankaferd Blood Stopper' (ABS) is a hemostatic agent produced as a mixture of five separate plant extracts. Provision of hemostasis by ABS is independent from coagulation factors and the standard coagulation cascade. Furthermore, ABS has an antimicrobial effect. In this article, we have presented a seven-year-old infant with IH on the lower lip who had been admitted with the symptoms of frequent bleedings and infection, and who was successfully treated with topical ABS in terms of control of bleeding and infection. To the best of our knowledge, this is the first reported case of IH that has been treated with ABS for bleeding.

Entities:  

Keywords:  Ankaferd Blood Stoper; bleeding; infantile hemangioma; infection

Year:  2012        PMID: 22993655      PMCID: PMC3443886     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  15 in total

1.  Successful management of a difficult case of radiation proctopathy with Ankaferd BloodStopper: a novel indication (with video).

Authors:  Ali Shorbagi; Bülent Sivri
Journal:  Gastrointest Endosc       Date:  2010-04-24       Impact factor: 9.427

Review 2.  Vascular masses of the head and neck.

Authors:  S E J Connor; C Flis; J D Langdon
Journal:  Clin Radiol       Date:  2005-08       Impact factor: 2.350

3.  Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper.

Authors:  H Goker; I C Haznedaroglu; S Ercetin; S Kirazli; U Akman; Y Ozturk; H C Firat
Journal:  J Int Med Res       Date:  2008 Jan-Feb       Impact factor: 1.671

4.  Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper.

Authors:  Suleyman Aydin
Journal:  J Int Med Res       Date:  2009 Jan-Feb       Impact factor: 1.671

5.  Antimicrobial activity of plant extract Ankaferd Blood Stopper.

Authors:  Nuriye Tasdelen Fisgin; Yeliz Tanriverdi Cayci; Ahmet Yilmaz Coban; Duzgun Ozatli; Esra Tanyel; Belma Durupinar; Necla Tulek
Journal:  Fitoterapia       Date:  2008-10-07       Impact factor: 2.882

6.  Upper gastrointestinal bleeding in a patient with defective hemostasis successfully treated with ankaferd blood stopper.

Authors:  Tugrul Purnak; Ersan Ozaslan; Yavuz Beyazit; Ibrahim C Haznedaroglu
Journal:  Phytother Res       Date:  2011-02       Impact factor: 5.878

7.  Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis.

Authors:  Aysenur Meric Teker; Arzu Yasemin Korkut; Volkan Kahya; Orhan Gedikli
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-13       Impact factor: 2.503

8.  Oral systemic administration of Ankaferd blood stopper has no short-term toxicity in an in vivo rabbit experimental model.

Authors:  Hasan Bilgili; Ozge Captug; Ali Kosar; Mevlut Kurt; Murat Kekilli; Ali Shorbagi; Ozlem Kar Kurt; Oktay Ozdemir; Hakan Goker; Ibrahim Celalettin Haznedaroglu
Journal:  Clin Appl Thromb Hemost       Date:  2009-07-14       Impact factor: 2.389

9.  Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability.

Authors:  Mevlut Kurt; Erkin Oztas; Sedef Kuran; Ibrahim K Onal; Murat Kekilli; Ibrahim C Haznedaroglu
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

10.  In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin.

Authors:  Handan S Cipil; Ali Kosar; Arif Kaya; Burak Uz; Ibrahim C Haznedaroglu; Hakan Goker; Oktay Ozdemir; Mustafa Koroglu; Serafettin Kirazli; Huseyin Cahit Firat
Journal:  Clin Appl Thromb Hemost       Date:  2009 May-Jun       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.